Bupropion hydrobromide and therapeutic applications
AssigneeBioavail Laboratories International S.R.L.
InventorsRobert WILLIAMS, Peter SILVERSTONE
Life of this patent
Estimating the term…
Abstract
Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
Claims19
A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
- wherein administration of an amount of a bupropion hydrobromide to a first rat results in less incidences of and/or less severe bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat;
- and
- wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
- wherein administration of about 100 mg/kg of a bupropion hydrobromide to a first rat results in less incidences of and/or severity of bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat;
- and
- wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
A method of treating a subject at risk of bupropion-induced seizures in need of bupropion treatment, the method comprising:
- administering a composition comprising bupropion hydrobromide to said subject in an amount sufficient to treat said subject.
A method of reducing incidences of bupropion-induced seizures comprising:
- administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
- wherein incidences of bupropion-induced seizures resulting from the administration of bupropion hydrobromide is less than incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride.
A method of reducing incidences of bupropion-induced seizures comprising:
- administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
- wherein administration of about 100 mg/kg of the bupropion hydrobromide to a first rat results in less incidences of bupropion-induced seizures when compared to incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat;
- and
- wherein the incidences of bupropion-induced seizures in the first and second rats are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
A method of reducing the incidences of bupropion induced seizures comprising coadministration of a bromide salt with a bupropion salt, wherein the bromide salt is administered in an amount of less than about 3.5 mg/kg.
A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
- wherein administration of about 100 mg/kg of a bupropion hydrobromide used to manufacture the composition to a first rat results in less incidences of and/or severity of bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat;
- and
- wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
Dependencies are inferred from the claim text.